Journals / JAREM / 2019 / Cilt: 9 - Sayı: 1

Investigation of Interleukin-17 Gene-152g/A Polymorphism and IL-17 Serum Levels in Patients with Cardiac Syndrome X

Kardiyak Sendrom X Hastalarında İnterlökin-17 Serum Seviyesi ve IL-17 Geni -152G/A Polimorfizminin Araştırılması

Journal
JAREM
Pages
23–28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this context, we foresee that statins can have a subsidiary effect on the CSX treatment to suppress the inflammatory response in patients in who the IL-17 levels were determined as significantly higher than in healthy controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cardiac syndrome X (CSX) can be defined as experiencing chest pain with angina by patients with normal coronary arteries.
📊
Key Findings & Data:It is accepted that both the number of B and T lymphocytes and expression of various proinflammatory cytokines released from those cells increases during inflammatory response.
💡
Conclusion & Impact:In this context, we foresee that statins can have a subsidiary effect on the CSX treatment to suppress the inflammatory response in patients in who the IL-17 levels were determined as significantly higher than in healthy controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Cardiac syndrome X (CSX) can be defined as experiencing chest pain with angina by patients with normal coronary arteries. Endothelial and microvascular dysfunction is responsible for the pathophysiology of the inflammatory CSX disease. Inflammation is especially an important factor in the progression of ischemic heart diseases. It is accepted that both the number of B and T lymphocytes and expression of various proinflammatory cytokines released from those cells increases during inflammatory response. Different proinflammatory cytokines are produced by activated macrophages and T lymphocytes. Since interleukin-17 (IL-17) induces many signaling molecules, which promote immune response and play a role in inflammation, it is assumed that IL-17 can play a role in the CSX pathogenesis. In our study, the relationship between CSX and IL-17 serum levels and the −152G/A polymorphism on IL-17 gene was investigated. Methods: Serum IL-17 levels of blood samples were analyzed from 100 patients with CSX and 101 healthy control individuals using the EnzymeLinked ImmunoSorbent Assay (ELISA) method. After the DNA isolation was performed from blood samples, the IL-17 gene-152G/A polymorphisms were detected based on the PCR-RFLP method for both patients and healthy individuals. The pomotor region of the IL-17 gene was amplified by the PCR method, and then, genotyping was performed using PCR products for the RFLP step. After that, obtained data for CSX patients and the healthy control group were compared using the statistical analysis. Results: When the IL-17 gene–152G/A polymorphism genotyping results of patients with CSX and healthy control individuals were compared, no statistically significant difference was observed in both genotypic and allelic distributions (p=0.218). The IL-17 serum levels were found to be statistically significantly higher in patients with CSX than in healthy controls (p<0.001). Conclusion: Endothelium plays a significant role in the regulation of vascular functions. Inflammatory response is generated against the endothelial activation in the CSX pathogenesis. An increase in the CRP levels, which is a marker of inflammation, is common for both coronary artery disease and CSX, associated with endothelial dysfunction. Helper T cells play important roles in cardiovascular diseases. IL-17 induces the expression of different proinflammatory cytokines and chemokines, participating in the tissue infiltration and destruction. There are also several studies that prove the significant role of proinflammatory IL-17, which is released from T cells, in cardiovascular diseases, supporting our results. In addition, it has been demonstrated that statins, having anti-inflammatory effects, inhibit the IL-17 gene expression and cytokine release. In this context, we foresee that statins can have a subsidiary effect on the CSX treatment to suppress the inflammatory response in patients in who the IL-17 levels were determined as significantly higher than in healthy controls.

Özet

Amaç: Kardiyak Sendrom X (KSX), normal koroner arterlere sahip hastalarda anjina ile birlikte göğüs ağrısının görülmesi olarak tanımlanabilir. İnflamatuvar bir hastalık olan KSX’in patofizyolojisinden endotelyal ve mikrovasküler disfonksiyon sorumlu tutulmaktadır. İnflamasyon, özellikle iskemik kalp hastalıklarının gelişmesinde oldukça etkili olan bir faktördür. İnflamatuvar yanıt sırasında, B ve T lenfositlerin sayısında ve bu hücrelerden salınan çeşitli proinflamatuvar sitokinlerin ekspresyonunda artış olduğu bilinmektedir. İnterlökin-17 (IL-17), immün yanıtı oluşturan ve inflamasyonda rol alan birçok sinyal molekülünü de indüklediği için; KSX patogenezinde rolü olabileceği düşünülmektedir. Çalışmamızda, IL-17 serum seviyeleri ve IL-17 geni üzerindeki -152G/A polimorfizmi ile KSX arasındaki ilişki incelenmiştir. Yöntemler: 100 KSX hastası ile 101 sağlıklı kontrol bireyden alınan kan örnekleri kullanılarak, ELISA metodu ile serum IL-17 seviyeleri ölçülmüştür. Örneklerden DNA izolasyonu yapıldıktan sonra, PZR-RFLP yöntemi kullanılarak; IL-17 geni -152G/A polimorfizminin belirlenmesi için genotipleme yapılmıştır. Bulgular: KSX hastaları ve sağlıklı kontrol bireylerin IL-17 geni -152G/A polimorfizmi sonuçları karşılaştırıldığında; genotip ve allelik dağılım açısından aralarında istatistiksel olarak anlamlı bir fark gözlenmedi (p=0,218). IL-17 serum seviyeleri ise; KSX hastalarında sağlıklı kontrol bireylere kıyasla istatistiksel olarak anlamlı derecede yüksek olarak bulunmuştur (p<0,001). Sonuç: KSX patogenezinde endotelyal aktivasyona karşı vücutta inflamatuvar yanıt oluşur. T hücrelerinden salınan proinflamatuvar IL-17’nin kardiyovasküler hastalıklardaki rolünü kanıtlayan, bizim çalışmamızı destekler nitelikte çeşitli çalışmalar mevcuttur. Bununla birlikte, anti-inflamatuvar etkiye sahip statin grubu ilaçların da IL-17 gen ekspresyonunu ve sitokin salınımını inhibe ettiği de gösterilmiştir. Bu bağlamda çalışmamızda, IL17 düzeyleri anlamlı derecede yüksek olarak belirlenen KSX’li hastalarda görülen inflamatuvar yanıtı baskılamak amacı ile hastalığın tedavisinde statinlerin yardımcı etki sağlayabileceğini öngörmekteyiz.

🔖

Cite This Article

ÖZER, Y. G., ÖNAL, B., ÖZEN, D., KANDAZ, C., DEMİR, B., AKKAN, A. G. (2019). Investigation of Interleukin-17 Gene-152g/A Polymorphism and IL-17 Serum Levels in Patients with Cardiac Syndrome X. JAREM, Cilt: 9 - Sayı: 1, 23–28. https://ajindex.com/articles/270371

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995; 25: 807-14.
  2. Buffon A, Rigattieri S, Santini SA, Ramazzotti V, Crea F, Giardina B, et al. Myocardial ischemia-reperfusion damage after pacing-induced tachycardia in patients with cardiac syndrome X. Am J Physiol Heart Circ Physiol 2000; 279: H2627-33. Dierich MP, Erdei A, Huemer H, Petzer A, Stauder R, Schulz TF, et al. Involvement of complement in B-cell, T-cell and monocyte/macrophage activation. Immunol Lett 1987; 14: 235-42.
  3. Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and inflammation: what is the link? Kidney Int Suppl 2003: 45-9.
  4. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 2006; 57: 505-28.
  5. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155: 5483-6.
  6. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002; 71: 1-8.
  7. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
  8. Michaelides A, Ryan JM, VanFossen D, Pozderac R, Boudoulas H. Exercise-induced QRS prolongation in patients with coronary artery disease: a marker of myocardial ischemia. Am Heart J 1993; 126: 1320-5.
  9. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986; 7: 479-83. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-8.
  10. Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 2013; 6: 660-7.
  11. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol 2000; 190: 343-8. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
  12. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol 2004; 114: 1265-73. Kaski JC.